Arcellx Inc (ACLX)
NASDAQ:ACLX
Top Page
Arcellx Inc
(NASDAQ:ACLX)
Select Model
Select Model
Rating:64Neutral
Price Target:
$122.00
▲(6.28% Upside)
Action:UpgradedDate:02/27/26
Score is balanced between weak fundamentals (no 2025 revenue, widening losses, and worsening cash burn) and strong external/market support from the announced takeout plus very strong price momentum. Negative earnings (negative P/E) remains a valuation headwind, but the corporate event materially offsets financial risk in the near term.
Positive Factors
Strategic acquisition by Gilead
A definitive acquisition by a large, experienced oncology acquirer materially reduces Arcellx's standalone funding and commercialization risk, consolidates economic upside for anito-cel, and accelerates scale and market access via Gilead’s commercial and manufacturing capabilities.
Negative Factors
Pre-commercial losses and revenue collapse
A return to zero product revenue and sharply larger operating losses signal persistent commercial immaturity and elevated operating leverage. Without commercialization or stable partner flows, sustained losses undermine long-term operational resilience and require external funding or M&A outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic acquisition by Gilead
A definitive acquisition by a large, experienced oncology acquirer materially reduces Arcellx's standalone funding and commercialization risk, consolidates economic upside for anito-cel, and accelerates scale and market access via Gilead’s commercial and manufacturing capabilities.
Read all positive factors
Arcellx Inc (ACLX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.71B
Dividend YieldN/A
Average Volume (3M)1.98M
Price to Earnings (P/E)―
Beta (1Y)0.82
Revenue Growth-76.96%
EPS Growth-425.41%
CountryUS
Employees163
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.00
Shares Outstanding58,479,813
10 Day Avg. Volume1,004,921
30 Day Avg. Volume1,975,801
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)9.12
Price to Sales (P/S)164.73
P/FCF Ratio-17.27
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue301.93
Enterprise Value/Gross Profit-465.89
Enterprise Value/Ebitda-33.99
Forecast
1Y Price Target
$112.85Price Target Upside-1.69% Downside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)-3.71
Revenue Forecast (FY)$73.66M
Arcellx Inc Business Overview & Revenue Model
Company Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clin...
How the Company Makes Money
Arcellx generates revenue primarily through the development and commercialization of its therapeutic products. The company may earn revenue from product sales once its therapies receive regulatory approval and are launched in the market. Additiona...
Arcellx Inc Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 22.29M | 107.94M | 110.32M | 0.00 | 0.00 |
| Gross Profit | 15.61M | 102.75M | 110.32M | -2.22M | 0.00 |
| EBITDA | -197.97M | -99.06M | -64.14M | -184.74M | -63.92M |
| Net Income | -228.93M | -107.35M | -70.69M | -188.68M | -64.97M |
Balance Sheet | |||||
| Total Assets | 603.99M | 711.33M | 825.13M | 313.82M | 128.78M |
| Cash, Cash Equivalents and Short-Term Investments | 450.33M | 587.58M | 702.02M | 254.84M | 104.62M |
| Total Debt | 96.26M | 54.08M | 97.63M | 88.13M | 0.00 |
| Total Liabilities | 201.64M | 256.54M | 339.75M | 108.86M | 250.30M |
| Stockholders Equity | 402.35M | 454.79M | 485.38M | 204.95M | -121.52M |
Cash Flow | |||||
| Free Cash Flow | -212.59M | -96.90M | 186.15M | -101.58M | -60.02M |
| Operating Cash Flow | -210.26M | -83.47M | 207.57M | -99.30M | -54.24M |
| Investing Cash Flow | 86.30M | -183.04M | -154.51M | -117.67M | -79.98M |
| Financing Cash Flow | 98.53M | -24.09M | 279.16M | 252.63M | 118.45M |
Arcellx Inc Technical Analysis
Positive
114.79
Price Trends
97.81
Positive
84.64
Positive
80.29
Positive
Market Momentum
3.84
Positive
80.71
Negative
66.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACLX, the sentiment is Positive. The current price of 114.79 is above the 20-day moving average (MA) of 114.61, above the 50-day MA of 97.81, and above the 200-day MA of 80.29, indicating a bullish trend. The MACD of 3.84 indicates Positive momentum. The RSI at 80.71 is Negative, neither overbought nor oversold. The STOCH value of 66.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACLX.
Arcellx Inc Risk Analysis
Arcellx Inc disclosed 88 risk factors in its most recent earnings report. Arcellx Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Arcellx Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $6.71B | -16.04 | -55.42% | ― | -76.96% | -425.41% | |
62 Neutral | $6.51B | -42.66 | -19.89% | ― | -35.39% | -72.97% | |
62 Neutral | $5.03B | -10.43 | -65.80% | ― | ― | -27.70% | |
56 Neutral | $5.20B | 141.40 | 8.20% | ― | 42.11% | ― | |
54 Neutral | $2.59B | -34.27 | -7.31% | ― | -84.07% | -157.71% | |
54 Neutral | $1.33B | -3.74 | -67.12% | ― | ― | -157.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
ACLX
Arcellx Inc
114.79
55.63
94.03%
PTGX
Protagonist Therapeutics
102.09
59.52
139.82%
APLS
Apellis Pharmaceuticals
40.69
21.08
107.50%
IMVT
Immunovant
24.73
9.83
65.97%
BEAM
Beam Therapeutics
25.44
9.07
55.41%
MLTX
MoonLake Immunotherapeutics
18.60
-17.38
-48.30%
Arcellx Inc Corporate Events
Business Operations and StrategyM&A TransactionsProduct-Related AnnouncementsRegulatory Filings and Compliance
Arcellx Advances Anito-cel as FDA Accepts BLA Filing
Positive
Feb 23, 2026
On February 22, 2026, Arcellx entered into a definitive merger agreement under which Gilead Sciences will acquire the company via a tender offer and follow-on merger for $115 in cash per share plus a $5 contingent value right, implying equity valu...
Business Operations and StrategyProduct-Related Announcements
Arcellx Reports Promising Phase 2 Study Results
Positive
Dec 8, 2025
On December 6, 2025, Arcellx, Inc. announced positive results from its Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel) for relapsed or refractory multiple myeloma, showing a 96% overall response rate and 74% complete response rat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.